Singh Ilina
BIOS Centre, London School of Economics and Political Science, UK.
Clin Child Psychol Psychiatry. 2007 Apr;12(2):167-82. doi: 10.1177/1359104507075920.
Stimulant drug treatments for Attention Deficit/Hyperactivity Disorder (ADHD) have been a particular target of ethical controversy and debate. Bioethicists have raised concerns about the implications of stimulant drug treatment for child authenticity, individuality, and enhancement. There is at present little empirical evidence to support or deny these concerns. This article presents data from a pilot interview study that investigated children's moral self-understandings in relation to ADHD diagnosis and stimulant drug treatment, with a focus on children's understandings of their authentic selves. Stimulant drug treatment does not appear to undermine a child's sense of personal authenticity: In this study, children reported that they believed a core dimension of their 'real' selves was persistently 'bad', despite medication. This finding complicates two bioethical assumptions: That the authentic person is inherently good, and that there is inherent value in the experience of having access to a core, authentic dimension of oneself. Some important preliminary clinical implications of these findings are discussed.
用于治疗注意力缺陷多动障碍（ADHD）的兴奋剂药物一直是伦理争议和辩论的一个特别焦点。生物伦理学家对兴奋剂药物治疗对儿童本真性、个性和强化的影响表示担忧。目前几乎没有实证证据来支持或反驳这些担忧。本文呈现了一项初步访谈研究的数据，该研究调查了儿童对ADHD诊断和兴奋剂药物治疗的道德自我理解，重点是儿童对其真实自我的理解。兴奋剂药物治疗似乎并未削弱儿童的个人本真感：在这项研究中，儿童报告称，尽管服用了药物，但他们认为自己“真实”自我的一个核心维度一直是“坏的”。这一发现使两个生物伦理假设变得复杂：一是真实的人本质上是善良的，二是能够接触到自身核心、真实维度的体验具有内在价值。文中讨论了这些发现的一些重要初步临床意义。
